Filing Details

Accession Number:
0001123292-15-001354
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-11-13 17:04:38
Reporting Period:
2015-11-11
Filing Date:
2015-11-13
Accepted Time:
2015-11-13 17:04:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175505 Five Prime Therapeutics Inc FPRX Pharmaceutical Preparations (2834) 260038620
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1578771 Julie Hambleton C/O Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco CA 94080
Evp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-11-11 10,000 $7.26 95,919 No 4 M Direct
Common Stock Disposition 2015-11-11 6,600 $34.75 89,319 No 4 S Direct
Common Stock Disposition 2015-11-11 3,400 $35.23 85,919 No 4 S Direct
Common Stock Acquisiton 2015-11-11 12,000 $11.14 97,919 No 4 M Direct
Common Stock Disposition 2015-11-11 12,000 $34.33 85,919 No 4 S Direct
Common Stock Disposition 2015-11-11 1,108 $35.33 84,811 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-11-11 10,000 $0.00 10,000 $7.26
Common Stock Employee Stock Option (right to buy) Disposition 2015-11-11 12,000 $0.00 12,000 $11.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,390 2023-07-18 No 4 M Direct
38,000 2024-08-21 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,700 Indirect By husband's IRA
Common Stock 64 Indirect By son's custodial account
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.03 to $35.02, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2, 3, and 4 to this Form 4.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.04 to $35.57, inclusive.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.69, inclusive.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.32 to $35.34, inclusive.
  5. The option began vesting on July 19, 2013, at a rate of 1/48th per month.
  6. The option began vesting on September 22, 2014, at a rate of 1/48th per month.